Advanz Pharma (OTCMKTS:CXRXF) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Advanz Pharma (OTCMKTS:CXRXF) from a buy rating to a hold rating in a research note published on Monday, reports.

According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “

Separately, ValuEngine lowered Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd.

Advanz Pharma stock opened at $14.69 on Monday. The stock has a market capitalization of $718.53 million, a PE ratio of 1.25 and a beta of 0.50. The company has a debt-to-equity ratio of 6.47, a quick ratio of 1.71 and a current ratio of 2.01. Advanz Pharma has a one year low of $12.72 and a one year high of $60.99. The firm’s fifty day moving average price is $15.56.

Advanz Pharma (OTCMKTS:CXRXF) last posted its quarterly earnings data on Friday, May 10th. The company reported ($0.16) EPS for the quarter. The company had revenue of $135.64 million during the quarter. Equities research analysts anticipate that Advanz Pharma will post -1.58 EPS for the current fiscal year.

Advanz Pharma Company Profile

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Read More: How liquidity affects the bid-ask spread

Get a free copy of the Zacks research report on Advanz Pharma (CXRXF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with's FREE daily email newsletter.